全文获取类型
收费全文 | 1281165篇 |
免费 | 98384篇 |
国内免费 | 1649篇 |
专业分类
耳鼻咽喉 | 16522篇 |
儿科学 | 42010篇 |
妇产科学 | 35816篇 |
基础医学 | 191447篇 |
口腔科学 | 35076篇 |
临床医学 | 120690篇 |
内科学 | 250301篇 |
皮肤病学 | 27812篇 |
神经病学 | 103983篇 |
特种医学 | 47368篇 |
外国民族医学 | 265篇 |
外科学 | 180642篇 |
综合类 | 25988篇 |
现状与发展 | 3篇 |
一般理论 | 599篇 |
预防医学 | 107001篇 |
眼科学 | 28415篇 |
药学 | 93908篇 |
6篇 | |
中国医学 | 1995篇 |
肿瘤学 | 71351篇 |
出版年
2019年 | 10818篇 |
2018年 | 14404篇 |
2017年 | 11005篇 |
2016年 | 12035篇 |
2015年 | 13806篇 |
2014年 | 19045篇 |
2013年 | 29043篇 |
2012年 | 39856篇 |
2011年 | 42320篇 |
2010年 | 24379篇 |
2009年 | 23335篇 |
2008年 | 39631篇 |
2007年 | 42418篇 |
2006年 | 41935篇 |
2005年 | 40987篇 |
2004年 | 39182篇 |
2003年 | 37419篇 |
2002年 | 36250篇 |
2001年 | 56084篇 |
2000年 | 57005篇 |
1999年 | 47901篇 |
1998年 | 12670篇 |
1997年 | 11502篇 |
1996年 | 11840篇 |
1995年 | 11967篇 |
1994年 | 11149篇 |
1993年 | 10478篇 |
1992年 | 38223篇 |
1991年 | 37739篇 |
1990年 | 36481篇 |
1989年 | 35300篇 |
1988年 | 32713篇 |
1987年 | 32038篇 |
1986年 | 30535篇 |
1985年 | 28795篇 |
1984年 | 21950篇 |
1983年 | 19172篇 |
1982年 | 11346篇 |
1979年 | 20909篇 |
1978年 | 15388篇 |
1977年 | 12741篇 |
1976年 | 11794篇 |
1975年 | 12787篇 |
1974年 | 15563篇 |
1973年 | 15336篇 |
1972年 | 14511篇 |
1971年 | 13548篇 |
1970年 | 12765篇 |
1969年 | 12054篇 |
1968年 | 11216篇 |
排序方式: 共有10000条查询结果,搜索用时 328 毫秒
1.
2.
3.
Clinical Oral Investigations - To evaluate the effect of membrane occlusiveness and experimental diabetes on early and late healing following guided bone regeneration. A total of 30 Wistar rats... 相似文献
4.
5.
Nanotherapy: New Approach for Impeding Hepatic Cancer Microenvironment via Targeting Multiple Molecular Pathways 下载免费PDF全文
Ahmed A Abd-Rabou Hanaa H Ahmed Safaa H MohamedSoheir E KotobMohamed S Kishta 《Asian Pacific journal of cancer prevention》2022,23(12):4261-4273
Objective: Hepatocellular carcinoma (HCC) microenvironment has been recognized as a key contributor for cancer progression, metastasis, and drug resistance. The crosstalk between tumor cells, the vascular endothelial growth factor (VEGF), and the chemokine (C-C motif) ligand 2 (CCL2) signaling networks mediates immunoinhibitory impact and facilitates tumor angiogenesis. The current investigation aimed at exploring the potent anti-cancer activity of the newly designed nano-based anti-cancer therapy comprising anti-VEGF drug, avastin (AV), and CCR2 antagonist (CR) to counteract HCC and tracking its mode of action in vivo. Methods: The prepared AV, CR, and AVCR nanoprototypes were characterized by nanoscale characterization techniques in our previous work. Here, they are applied for unearthing their anti-cancer properties / mechanisms in hepatic cancer-induced rats via analyzing protein levels and genetic expression of the elements incorporated in the angiogenesis, apoptosis, and metastasis signalling pathways. Results: The present results revealed a significant down-regulation in the angiogenesis, survival and metastasis indices along with up-regulation in the pro-apoptotic mediators upon treatment of hepatic cancer-bearing rats with the novel synthesized nanomaterials when compared with the untreated counterparts. We showed across HCC model that anti-VEGF in combination with CCR2 antagonism therapy leads to sensitization and enhanced tumor response over anti-VEGF or CCR2 antagonism monotherapy, particularly in its nanoscale formulation. Conclusion: The present approach provides new mechanistic insights into the powerful anti-hepatic cancer advantage of the novel nanoprototypes which is correlated with modulating critical signal transduction pathways implicated in tumor microenviroment such as angiogenesis, apoptosis and metastasis. This research work presents a substantial foundation for future studies focused on prohibiting cancer progression and recovery by targeting tumor microenviroment. 相似文献
6.
Anna Ugalde BA PhD Victoria White BA MA PhD Nicole M. Rankin BA MSc PhD Christine Paul BA PhD Catherine Segan BA PhD Sanchia Aranda RN BAppSci MN PhD Anna Wong Shee BSc BAppSc PhD Alison M. Hutchinson RN BApp Sci MBioth PhD Patricia M. Livingston BA PhD 《CA: a cancer journal for clinicians》2022,72(3):266-286
Smoking cessation reduces the risk of death, improves recovery, and reduces the risk of hospital readmission. Evidence and policy support hospital admission as an ideal time to deliver smoking-cessation interventions. However, this is not well implemented in practice. In this systematic review, the authors summarize the literature on smoking-cessation implementation strategies and evaluate their success to guide the implementation of best-practice smoking interventions into hospital settings. The CINAHL Complete, Embase, MEDLINE Complete, and PsycInfo databases were searched using terms associated with the following topics: smoking cessation, hospitals, and implementation. In total, 14,287 original records were identified and screened, resulting in 63 eligible articles from 56 studies. Data were extracted on the study characteristics, implementation strategies, and implementation outcomes. Implementation outcomes were guided by Proctor and colleagues' framework and included acceptability, adoption, appropriateness, cost, feasibility, fidelity, penetration, and sustainability. The findings demonstrate that studies predominantly focused on the training of staff to achieve implementation. Brief implementation approaches using a small number of implementation strategies were less successful and poorly sustained compared with well resourced and multicomponent approaches. Although brief implementation approaches may be viewed as advantageous because they are less resource-intensive, their capacity to change practice in a sustained way lacks evidence. Attempts to change clinician behavior or introduce new models of care are challenging in a short time frame, and implementation efforts should be designed for long-term success. There is a need to embrace strategic, well planned implementation approaches to embed smoking-cessation interventions into hospitals and to reap and sustain the benefits for people who smoke. 相似文献
7.
Osama Y Safdar Rana M Baghdadi Sereen A Alahmadi Bana E Fakieh Amaal M Algaydi 《World Journal of Clinical Pediatrics》2022,11(1):14-26
Whether the underlying mutations are homozygous, heterozygous, or co-inherited with other hemoglobinopathies, sickle cell disease is known to afflict the kidneys, leading to the clinical entity known as sickle cell nephropathy (SCN). Although common, SCN remains diagnostically elusive. Conventional studies performed in the context of renal disorders often fail to detect early stage SCN. This makes the quest for early diagnosis and treatment more challenging, and it increases the burden of chronic kidney disease-related morbidity among patients. Novel diagnostic tools have been employed to overcome this limitation. In this study, we discuss various biomarkers of SCN, including those employed in clinical practice and others recently identified in experimental settings, such as markers of vascular injury, endothelial dysfunction, tubulo-glomerular damage, and oxidative stress. These include kidney injury molecule-1, monocyte chemoattractant protein-1, N-acetyl-B-D-glucosaminidase, ceruloplasmin, orosomucoid, nephrin, and cation channels, among others. Furthermore, we explore the potential of novel biomarkers for refining diagnostic and therapeutic approaches and describe some obstacles that still need to be overcome. We highlight the importance of a collaborative approach to standardize the use of promising new biomarkers. Finally, we outline the limitations of conventional markers of renal damage as extensions of the pathogenic process occurring at the level of the organ and its functional subunits, with a discussion of the expected pattern of clinical and biochemical progression among patients with SCN. 相似文献
8.
9.